Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerSrivatsan Raghavan, Alex K. Shalek, Peter Winter et al.|Cell|2021Cited by 586
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapiesHongbin Ji, Kwok‐Kin Wong, Danan Li et al.|Cancer Cell|2006Cited by 451
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M. Sholl, Laura E. MacConaill, T. Khanh et al.|JCI Insight|2016Cited by 447
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Jeffrey R. Infante et al.|Cancer Discovery|2017Cited by 418
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 393